Studies regarding TKI resistance in leukemia have mostly centered on cancer genetic alterations [13, 14], for example, acquired mutations (which happen in about 1/3 of progressive cases) in the kinase domains of BCR::ABL1 that reduce or even fully impair TKIs’ binding to ABL kinase. Here, ABL1 is linked to cancer.